EMMESSA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Upcoming Events:
Quarterly Results
Events:
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Emmessar Biotech&Nut do?
Emmessar Biotech & Nutrition Ltd specializes in manufacturing Super Speciality Fine Chemicals and has diversified into Biotechnology & Healthcare. They offer a range of products including Calmcream, Magicream, and Supportt Joint.
Who are the competitors of Emmessar Biotech&Nut?
Emmessar Biotech&Nut major competitors are Saroja Pharma Ind, Norris Medicines, Parmax Pharma, Link Pharma Chem, Colinz Laboratories, Hamps Bio, Rekvina Labs. Market Cap of Emmessar Biotech&Nut is ₹14 Crs. While the median market cap of its peers are ₹14 Crs.
Is Emmessar Biotech&Nut financially stable compared to its competitors?
Emmessar Biotech&Nut seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Emmessar Biotech&Nut pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Emmessar Biotech&Nut latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Emmessar Biotech&Nut allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments
How strong is Emmessar Biotech&Nut balance sheet?
Balance sheet of Emmessar Biotech&Nut is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Emmessar Biotech&Nut improving?
The profit is oscillating. The profit of Emmessar Biotech&Nut is ₹0.32 Crs for Mar 2025, ₹0.75 Crs for Mar 2024 and ₹0.5 Crs for Mar 2023
Is the debt of Emmessar Biotech&Nut increasing or decreasing?
Yes, The net debt of Emmessar Biotech&Nut is increasing. Latest net debt of Emmessar Biotech&Nut is -₹7.19 Crs as of Sep-25. This is greater than Mar-25 when it was -₹13.74 Crs.
Is Emmessar Biotech&Nut stock expensive?
Emmessar Biotech&Nut is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Emmessar Biotech&Nut is 58.25, while 3 year average PE is 29.35. Also latest EV/EBITDA of Emmessar Biotech&Nut is 0.0 while 3yr average is 4.46.
Has the share price of Emmessar Biotech&Nut grown faster than its competition?
Emmessar Biotech&Nut has given better returns compared to its competitors. Emmessar Biotech&Nut has grown at ~-21.81% over the last 1yrs while peers have grown at a median rate of -30.48%
Is the promoter bullish about Emmessar Biotech&Nut?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Emmessar Biotech&Nut is 59.53% and last quarter promoter holding is 59.53%.
Are mutual funds buying/selling Emmessar Biotech&Nut?
The mutual fund holding of Emmessar Biotech&Nut is stable. The current mutual fund holding in Emmessar Biotech&Nut is 0.05% while previous quarter holding is 0.05%.
